Direct KRAS inhibition: progress, challenges, and a glimpse into the future

Expert Rev Anticancer Ther. 2020 Jun;20(6):437-440. doi: 10.1080/14737140.2020.1760093. Epub 2020 Apr 28.

Authors

Dimitra Grapsa¹, Konstantinos Syrigos¹

Affiliation

¹ Oncology Unit, 3rd Department of Medicine, Medical School, National and Kapodistrian University of Athens , Athens, Greece.

PMID: 32320301
DOI: 10.1080/14737140.2020.1760093

No abstract available

Keywords: Direct targeting; KRAS; KRAS(G12C); inhibitor; treatment response.

Publication types

Editorial

MeSH terms

Animals
Antineoplastic Agents / pharmacology
Drug Development
Humans
Molecular Targeted Therapy*
Neoplasms / drug therapy*
Neoplasms / genetics
Proto-Oncogene Proteins p21(ras) / antagonists & inhibitors*
Proto-Oncogene Proteins p21(ras) / genetics

Substances

Antineoplastic Agents
KRAS protein, human
Proto-Oncogene Proteins p21(ras)